NovAliX Enters Collaboration with Teijin Pharma

NovAliX has announced that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Ltd of Tokyo, Japan.

Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX will initially use its protein biochemistry expertise in combination with its comprehensive biophysical technology platform. NovAliX will apply its proprietary Graffinity SPR-based screening

technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterisation of selected small molecule hit structures.

This arrangement represents NovAliX’ first discovery collaboration with Teijin Pharma. Under the terms of the  agreement NovAliX will receive technology access fees as well as further research funding payments. Financial  details of the transaction were not disclosed.

Stephan Jenn, President of NovAliX, stated: ”We are confident that this alliance will be very productive and are proud to be associated with Teijin’s technology-driven team. In this collaboration Teijin will have the opportunity to leverage the entire spectrum of our capabilities in biochemistry, biophysics and medicinal chemistry. For NovAliX this integrated collaboration represents a significant milestone as Teijin is the second Japanese pharmaceutical company to

partner with us this year.

This alliance underlines again the competitive edge of our scientific expertise and biophysical technologies as well as our commitment to serve the Japanese pharmaceutical research market that is strongly driven by science and innovation.”